177Lu-JH04 in Patients with FAP-Positive Tumors

Phase 0 Recruiting 9 enrolled First Affiliated Hospital of Fujian Medical University

Non-randomizedSequentialSingle-blindTreatment

Summary

This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.

Timeline

Start: 2024-08-21
Primary completion: 2025-08-31
Completion: 2025-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-JH04	Unknown	3700 mbq	Intravenous
Subject	177Lu-JH04	Unknown	5550 mbq	Intravenous
Subject	177Lu-JH04	Unknown	7400 mbq	Intravenous

Indications

No indication recorded.